Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 401–500 of 1,005
Harada, H., Kizaka-Kondoh, S., & Hiraoka, M. (2005) · Molecular Imaging · doi:10.1162/15353500200505112 · Cited by 101
The role of HIF prolyl hydroxylases in tumour growth
Jokilehto, T., & Jaakkola, P. M. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01030.x · Cited by 101
“The formation of pVHL-HIF complex leads to polyubiquitylation and subsequently to the destruction of HIF- subunits in proteasomes [26–30].”
BackgroundSrc promotes GTPase activity of Ras via tyrosine 32 phosphorylation
Bunda, S., Heir, P., Srikumar, T., Cook, J. D., Burrell, K., Kano, Y., Lee, J. E., Zadeh, G., Raught, B., & Ohh, M. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406559111 · Cited by 100
Self-citationHypoxia and Senescence: The Impact of Oxygenation on Tumor Suppression
Welford, S. M., & Giaccia, A. J. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0065 · Cited by 108
“VHL is particularly relevant for this discussion, as it is the primary regulator of the HIF-a subunits under oxic conditions, directing proteasome-mediated degradation that inactivates HIF function (81).”
BackgroundCellular mechanisms in retinal vascular development
Gariano, R. F. (2003) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(02)00062-9 · Cited by 102
The multifaceted von Hippel–Lindau tumour suppressor protein
Robinson, C. M., & Ohh, M. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.026 · Cited by 96
“Despite a growing knowledge of the various functions of VHL , the most extensively characterised E3 ubiquitin ligase function of pVHL to date, and arguably its most important, is its regulation of the a -subunit of the HIF family of transcription factors [44– 46].”
BackgroundSelf-citationHypoxia‑inducible factors in hepatocellular carcinoma (Review)
Guo, Y., Xiao, Z., Liu, Y., Gao, Y., Zhu, Q., Hu, L., Huang, D., & Xu, Q. (2019) · Oncology Reports · doi:10.3892/or.2019.7397 · Cited by 120
Molecular basis of inherited diseases: a structural perspective
Steward, R. E., MacArthur, M. W., Laskowski, R. A., & Thornton, J. M. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00195-1 · Cited by 113
A Role for von Hippel-Lindau Protein in Pancreatic β-Cell Function
Puri, S., Cano, D. A., & Hebrok, M. (2009) · Diabetes · doi:10.2337/db08-0749 · Cited by 97
“The von Hippel-Lindau tumor suppressor gene product (VHL) is an essential component of the cellular response to hypoxia (8,9).”
BackgroundUnderstanding the Importance of Smart Drugs in Renal Cell Carcinoma
Patard, J., Rioux-Leclercq, N. C., & Fergelot, P. (2006) · European Urology · doi:10.1016/j.eururo.2006.01.016 · Cited by 110
“Under normoxic conditions, the VHL elonginC/B-Cul2 complex targets HIF-1a, leading to their polyubiquitination and proteasomal degradation [16,17].”
BackgroundLukashev, D., Caldwell, C., Ohta, A., Chen, P., & Sitkovsky, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104782200 · Cited by 97
Regression of pathological cardiac hypertrophy: Signaling pathways and therapeutic targets
Hou, J., & Kang, Y. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.06.006 · Cited by 108
“The hydroxylated HIF-1α is recognized by the von Hippel-Lindau protein (pVHL), which is a constituent of a ubiquitin ligase complex, targeting the HIF-1α subunit for degradation by the proteasome in the cytoplasm (Masson et al., 2001; Maxwell et al., 1999; Ohh et al., 2000; Tanimoto et al., 2000).”
BackgroundThe pVHL-HIF-1 system: A key mediator of oxygen homeostasis
Maxwell, P., Pugh, C. W., & Ratcliffe, P. J. (2001) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-3401-0_24 · Cited by 100
Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects
Ferro, M., Musi, G., Marchioni, M., Maggi, M., Veccia, A., Giudice, F. D., Barone, B., Crocetto, F., Lasorsa, F. M., Antonelli, A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054615 · Cited by 109
Analysis of gene expression changes in a cellular model of Parkinson disease
Ryu, E. J., Angelastro, J. M., & Greene, L. A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.08.016 · Cited by 95
Chlamydia pneumoniae directly interferes with HIF-1α stabilization in human host cells
Rupp, J., Gieffers, J., Klinger, M., van Zandbergen, G., Wrase, R., Maass, M., Solbach, W., Deiwick, J., & Hellwig-Burgel, T. (2007) · Cellular Microbiology · doi:10.1111/j.1462-5822.2007.00948.x · Cited by 95
“Prolyl-hydroxylated HIF-1 is captured immediately by the von Hippel–Lindau protein (Ivan et al., 2001; Jaakkola et al., 2001), which is the substraterecognizing subunit of an E3 ubiquitin ligase (Maxwell et al., 1999; Ohh et al., 2000).”
BackgroundLee, S. H., Che, X., Jeong, J., Choi, J., Lee, Y., Lee, Y. H., Bae, S.-C., & Lee, Y. M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340232 · Cited by 99
“Ubiquitination of HIF-1 is mediated by interaction with the von Hippel-Lindau protein (pVHL),(2) a tumor suppressor (19).”
BackgroundVHLinactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment
Rathmell, W. K., & Chen, S. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.1.63 · Cited by 107
“This domain, encompassing variably residues 63-155 has been shown to be essential for the interaction with both atypical protein kinase C and the hydroxylated forms of the hypoxia inducible factor (HIF) [16,17].”
BackgroundBan, H. S., Kim, B., Lee, H., Kim, H. M., Harmalkar, D. S., Nam, M., Park, S., Lee, K., Park, J.-T., Kim, I., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.235 · Cited by 102
“and dimerizes with the HIF-1β subunit in the nucleus under conditions of hypoxia.(2,3) These HIF-1α/β heterodimers subsequently bind to hypoxia-response elements (HREs) (5′-RCGTG-3′, where R is A or G) in the promoters of target genes”
BackgroundTargeting Hypoxia Signaling for Perioperative Organ Injury
Yuan, X., Lee, J. W., Bowser, J. L., Neudecker, V., Sridhar, S., & Eltzschig, H. K. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002288 · Cited by 102
The HIF and other quandaries in VHL disease
Tarade, D., & Ohh, M. (2017) · Oncogene · doi:10.1038/onc.2017.338 · Cited by 97
Self-citationIntegral UBL domain proteins: a family of proteasome interacting proteins
Hartmann‐Petersen, R., & Gordon, C. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2003.12.006 · Cited by 106
Liu, J., & Nussinov, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707401105 · Cited by 95
The interplay of NR4A receptors and the oncogene–tumor suppressor networks in cancer
Beard, J. A., Tenga, A., & Chen, T. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.11.009 · Cited by 98
A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology
Acker, T., & Plate, K. H. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0355-1 · Cited by 112
“Several studies went on to show that the pVHL β-domain binds to the ODD of HIF-α subunits, which involves hydroxylation of specific prolyl residues, while the pVHL α-domain mediates interaction with elongin C [32, 33, 34, 35, 36, 37, 38].”
BackgroundAngiogenesis and G-protein-coupled receptors: signals that bridge the gap
Richard, D. E., Vouret‐Craviari, V., & Pouysségur, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204193 · Cited by 102
“The mechanism by which HIF-1a is targeted for degradation is now being uncovered (Cockman et al., 2000; Maxwell et al., 1999; Ohh et al., 2000; Tanimoto et al., 2000).”
BackgroundNa, X., Duan, H. O., Messing, E. M., Schoen, S. R., Ryan, C. K., di Sant'Agnese, P. A., Golemis, E. A., & Wu, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg410 · Cited by 95
Role of CBP in regulating HIF-1-mediated activation of transcription
Ruas, J. L., Poellinger, L., & Pereira, T. (2005) · Journal of Cell Science · doi:10.1242/jcs.01617 · Cited by 95
“…recognized by the von Hippel-Lindau tumor suppressor protein which is part of an E3 ubiquitin ligase complex (Cockman et al., 2000; Ivan et al., 2001; Jaakkola et al., 2001; Kamura et al., 2000; Masson et al., 2001; Ohh et al., 2000; Pereira et al., 2003; Tanimoto et al., 2000; Yu et al., 2001).”
BackgroundYuen, J. S. P., Cockman, M. E., Sullivan, M., Protheroe, A. S., Turner, G. D. H., Roberts, I. S. D., Pugh, C. W., Werner, H., & Macaulay, V. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210474 · Cited by 108
Mitochondrial Regulation of Oxygen Sensing
Chandel, N. S. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-60761-500-2_22 · Cited by 91
Pseudohypoxic Pathways in Renal Cell Carcinoma
Bratslavsky, G., Sudarshan, S., Neckers, L., & Linehan, W. M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2510 · Cited by 89
Perrotta, S., Nobili, B., Ferraro, M., Migliaccio, C., Borriello, A., Cucciolla, V., Martinelli, V., Rossi, F., Punzo, F., Cirillo, P., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2422 · Cited by 93
Insights into Cullin-RING E3 Ubiquitin Ligase Recruitment: Structure of the VHL-EloBC-Cul2 Complex
Nguyen, H. C., Yang, H., Fribourgh, J. L., Wolfe, L. S., & Xiong, Y. (2015) · Structure · doi:10.1016/j.str.2014.12.014 · Cited by 96
“Under normoxic conditions, VHL targets the transcription factor hypoxia-inducible factor-1a (HIF-1a) for ubiquitylation and subsequent degradation by the proteasome (Ohh et al., 2000).”
Hypoxia and Regulation of Cancer Cell Stemness
Yun, Z., & Lin, Q. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5915-6_2 · Cited by 89
“tumor suppressor gene result in loss of function of the VHL tumor suppressor protein and consequent activation of the HIF pathway under normoxia, which promotes RCC development (Ohh et al. 2000; Maxwell et al. 1999).”
BackgroundHypoxia-dependent activation of HIF into a transcriptional regulator
Ruas, J. L., & Poellinger, L. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.04.001 · Cited by 102
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Formenti, F., Beer, P. A., Croft, Q. P. P., Dorrington, K. L., Gale, D. P., Lappin, T. R. J., Lucas, G. S., Maher, E. R., Maxwell, P. H., McMullin, M. F., et al. (2011) · The FASEB Journal · doi:10.1096/fj.10-177378 · Cited by 92
Posttranslationale Proteinmodifikation: die Chemie der Proteomdiversifizierung
Walsh, C. T., Garneau‐Tsodikova, S., & Gatto, G. J. J. (2005) · Angewandte Chemie · doi:10.1002/ange.200501023 · Cited by 94
eEF1A Is a Novel Component of the Mammalian Nuclear Protein Export Machinery
Khacho, M., Mekhail, K., Pilon‐Larose, K., Pause, A., Côté, J., & Lee, S. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-06-0562 · Cited by 92
“C157 only assembled with the 48-kDa protein but not with the core ubiquitin ligase component Cullin-2 or other associated proteins, as expected (Figure 1C and Ohh et al., 2000; Bonicalzi et al., 2001).”
BackgroundHansen, W. J., Ohh, M., Moslehi, J. J., Kondo, K., Kaelin, W. G., & Welch, W. J. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.6.1947-1960.2002 · Cited by 98
Self-citationAn Important Role for DNMT3A-Mediated DNA Methylation in Cardiomyocyte Metabolism and Contractility
Madsen, A., Höppner, G., Krause, J., Hirt, M. N., Laufer, S. D., Schweizer, M., Tan, W. L. W., Mosqueira, D., Anene-Nzelu, C. G., Lim, I. Y., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044444 · Cited by 96
Chen, R., Xu, M., Hogg, R. T., Li, J., Little, B. B., Gerard, R. D., & Garcia, J. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.244780 · Cited by 99
Zhai, W., Sun, Y., Jiang, M., Wang, M., Gasiewicz, T. A., Zheng, J., & Chang, C. (2016) · Oncogene · doi:10.1038/onc.2016.19 · Cited by 94
Watanabe, Y., Murdoch, C. E., Sano, S., Ido, Y., Bachschmid, M. M., Cohen, R. A., & Matsui, R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524198113 · Cited by 87
“In normoxia, HIF-1α is hydroxylated by oxygen-dependent prolyl hydroxylase, and hydroxylated HIF-1α is ubiquitinated by attachment of the E3 ubiquitin ligase, von Hippel–Lindau tumor suppressor protein (pVHL), to the ODD leading to proteasomal degradation (16, 17).”
BackgroundNakaigawa, N., Yao, M., Baba, M., Kato, S., Kishida, T., Hattori, K., Nagashima, Y., & Kubota, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0617 · Cited by 87
pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition
Tang, N., Mack, F. A., Haase, V. H., Simon, M. C., & Johnson, R. S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2519-2530.2006 · Cited by 102
Roberts, A. M., Watson, I. R., Evans, A. J., Foster, D. A., Irwin, M. S., & Ohh, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1770 · Cited by 88
Self-citationAutophagy mediates HIF2α degradation and suppresses renal tumorigenesis
Liu, X.-D., Yao, J., Tripathi, D. N., Ding, Z., Xu, Y., Sun, M., Zhang, J., Bai, S., Germán, P., Hoang, A. G., et al. (2014) · Oncogene · doi:10.1038/onc.2014.199 · Cited by 95
“No further increase in HIF2α amount was observed in cells expressing VHL W117R mutant after bafilomycin A1 treatment (Figure 2F).”
MethodInfluentialTang, T. T.-L., & Lasky, L. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302042200 · Cited by 88
Tumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies
Ciepła, J., & Smolarczyk, R. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01501-1 · Cited by 93
Functions of the Per/ARNT/Sim Domains of the Hypoxia-inducible Factor
Yang, J., Zhang, L., Erbel, P. J. A., Gardner, K. H., Ding, K., Garcia, J. A., & Bruick, R. K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501755200 · Cited by 87
Diabetic nephropathy: are there new and potentially promising therapies targeting oxygen biology?
Miyata, T., Suzuki, N., & de Strihou, C. V. Y. (2013) · Kidney International · doi:10.1038/ki.2013.74 · Cited by 88
Expression of hypoxia‐inducible factor 1α in tumours of patients with glioblastoma
Søndergaard, K. L., Hilton, D. A., Penney, M., Ollerenshaw, M., & Demaine, A. G. (2002) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2002.00391.x · Cited by 87
Yan, L., Colandrea, V. J., & Hale, J. J. (2010) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2010.510836 · Cited by 86
“, VHL), elognin B, elongin C, Cul2, and Rbx1 and subsequently degraded by the S26 proteasome, thus, downregulating the expression of HIF genes [48-51].”
BackgroundBrower, C. S., Sato, S., Tomomori-Sato, C., Kamura, T., Pause, A., Stearman, R., Klausner, R. D., Malik, S., Lane, W. S., Sorokina, I., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162424199 · Cited by 83
The structure and regulation of Cullin 2 based E3 ubiquitin ligases and their biological functions
Cai, W., & Yang, H. (2016) · Cell Division · doi:10.1186/s13008-016-0020-7 · Cited by 91
“The CRL2 ligase complex could bind to HIFα through the β domain of VHL, promote ubiquitination and proteasomal degradation of HIFα [42, 43].”
BackgroundGenbačev, O., Krtolica, A., Kaelin, W. G., & Fisher, S. J. (2001) · Developmental Biology · doi:10.1006/dbio.2001.0231 · Cited by 91
Self-citationYu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001) · PubMed · Cited by 95
Hofer, T., Desbaillets, I., Höpfl, G., Gassmann, M., & Wenger, R. H. (2001) · The FASEB Journal · doi:10.1096/fj.01-0546fje · Cited by 84
Pawlus, M. R., & Hu, C.-J. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.05.018 · Cited by 84
Responding to Hypoxia: Lessons From a Model Cell Line
Seta, K. A., Spicer, Z., Yuan, Y., Lu, G., & Millhorn, D. E. (2002) · Science's STKE · doi:10.1126/stke.2002.146.re11 · Cited by 80
Luo, J. C., & Shibuya, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204228 · Cited by 107
“The ubiquitin-proteasome system plays a pivotal role in the degradation of HIF a subunits, which is negatively regulated by the tumor suppressor von hippel-lindau (VHL) protein (Kaelin and Maher, 1998; Maxwell et al., 1999; Cockman et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000).”
BackgroundRytkönen, K. T., Vuori, K. A. M., Primmer, C. R., & Nikinmaa, M. (2007) · Comparative Biochemistry and Physiology Part D Genomics and Proteomics · doi:10.1016/j.cbd.2007.03.001 · Cited by 92
Peng, J., Lai, Z. G., Fang, Z. L., Xing, S., Kang, H., Chen, H., Jin, Q., Zhou, Q., Shen, W. J., Dong, Q. N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112744 · Cited by 86
Xu, Y., Zuo, Y., Zhang, H., Kang, X., Fei, Y., Yi, Z., Liu, M., Yeh, E. T. H., Chen, G., & Cheng, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164236 · Cited by 86
Furukawa, M., Ohta, T., & Xiong, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108565200 · Cited by 83
Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022) · Cancers · doi:10.3390/cancers14051259 · Cited by 83
“Upon binding, pVHL recruits elongin C, elongin B, cullin-2, and ring-box 1 proteins, creating the pVHL complex which together serve as the E3 ubiquitin ligase [97].”
BackgroundDiabetic nephropathy: a disorder of oxygen metabolism?
Miyata, T., & de Strihou, C. V. Y. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.211 · Cited by 86
Esteban-Barragán, M. A., Ávila, P., Álvarez-Tejado, M., Gutiérrez, M. D. C., García-Pardo, A., Sánchez‐Madrid, F., & Landázuri, M. O. (2002) · PubMed · Cited by 83
EGLN3 Prolyl Hydroxylase Regulates Skeletal Muscle Differentiation and Myogenin Protein Stability
Fu, J., Menzies, K. E., Freeman, R. S., & Taubman, M. B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m608748200 · Cited by 92
Haase, V. H. (2005) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2005.03.006 · Cited by 89
Lee, D., & Lee, Y. J. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21851 · Cited by 84
“QUERCETIN INHIBITS HYPOXIA-INDUCED ACCUMULATION OF HIF-1a IN A PROTEASOMAL-INDEPENDENT MANNER Under normoxic conditions, HIF-1a protein is hydroxylated at Pro-402 and Pro-564 residues and is degraded rapidly and continuously by ubiquitination and the proteasomal system [Lisztwan et al., 1999; Ohh et al., 2000].”
BackgroundHypoxia-inducible factors, hypoxia, and tumor angiogenesis
Gruber, M., & Simon, M. C. (2006) · Current Opinion in Hematology · doi:10.1097/01.moh.0000219663.88409.35 · Cited by 87
Chintala, S., Najrana, T., Toth, K., Cao, S., Durrani, F. A., Pili, R., & Rustum, Y. M. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-293 · Cited by 79
“Under aerobic conditions, HIF-1α is hydroxylated at 402 and 564 proline molecules by PHDs and recognized by VHL and further degraded by proteasome [42,43].”
BackgroundGao, R. Y., Wang, M., Liu, Q., Feng, D., Wen, Y., Xia, Y., Colgan, S. P., Eltzschig, H. K., & Ju, C. (2020) · Hepatology · doi:10.1002/hep.30954 · Cited by 79
“Under normoxic conditions, the prolyl hydroxylase domain (PHD) enzyme binds to the α-subunit and causes it to be degraded by the von Hippel-Lindau complex.(21,22) During hypoxic conditions, PHD is inactivated and the HIF α-subunit is stabilized and able to translocate into the nucleus and heterodimerize with the β-sub…”
BackgroundDexamethasone impairs hypoxia-inducible factor-1 function
Wagner, A. E., Huck, G., Stiehl, D. P., JELKMANN, W. E. B., & Hellwig‐Bürgel, T. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.061 · Cited by 85
Russell, R. C., Sufan, R. I., Zhou, B. R., Heir, P., Bunda, S., Sybingco, S. S., Greer, S. N., Roche, O., Heathcote, S. A., Chow, V. W. K., et al. (2011) · Nature Medicine · doi:10.1038/nm.2370 · Cited by 83
Self-citationThe von Hippel-Lindau Tumor Suppressor Stabilizes Novel Plant Homeodomain Protein Jade-1
Zhou, M. I., Wang, H., Ross, J. J., Kuzmin, I., Xu, C., & Cohen, H. T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205040200 · Cited by 80
Igarashi, H., Esumi, M., Ishida, H., & Okada, K. (2002) · Cancer · doi:10.1002/cncr.10635 · Cited by 81
Galbán, S., Fan, J., Martindale, J. L., Cheadle, C., Hoffman, B., Woods, M. P., Temeles, G., Brieger, J., Decker, J., & Gorospe, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2316-2328.2003 · Cited by 82
Zhang, C., Yang, C., Feldman, M. J., Wang, H., Pang, Y., Maggio, D. M., Zhu, D., Nesvick, C. L., Dmitriev, P., Bullova, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18125 · Cited by 80
“We investigated HIF-1α and HIF-2α levels after giving SAHA in the presence/absence of MG-132, a 26S proteosome inhibitor that reverses pVHL ubiquitindependent degradation [63-67].”
BackgroundHypoxia Regulation of Gene Transcription
Caro, J. (2001) · High Altitude Medicine & Biology · doi:10.1089/152702901750265251 · Cited by 81
“Further work has indicated that the VHL protein interacts with the ODD domain of HIF-1 a and targets it for ubiquitination (Cockman et al., 2000; Ohh et al., 2000; Tanimoto et al., 2000).”
Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia
Suliman, H. B., Ali, M., & Piantadosi, C. A. (2004) · Blood · doi:10.1182/blood-2003-07-2240 · Cited by 79
Hypoxia Inactivates the VHL Tumor Suppressor through PIASy-Mediated SUMO Modification
Cai, Q., Verma, S. C., Kumar, P., Ma, M., & Robertson, E. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009720 · Cited by 76
“The best-characterized function of VHL is as an adaptor for targeting HIFa for proteolytic degradation [5,6], and”
BackgroundStruckmann, K., Mertz, K. D., Steu, S., Storz, M., Staller, P., Krek, W., Schraml, P., & Moch, H. (2008) · The Journal of Pathology · doi:10.1002/path.2310 · Cited by 89
“This observation is in line with the ability of both pVHL isoforms to bind and target HIF-α subunits for ubiquitination [31], consequently leading to inactivation of HIF-induced transcription.”
BackgroundZou, X., Jiang, Y., Liu, L., Zhang, Z., & Zheng, Y. (2010) · BMC Plant Biology · doi:10.1186/1471-2229-10-189 · Cited by 80
Schultz, L., Chaux, A., Albadine, R., Hicks, J. L., Kim, J., Marzo, A. M. D., Allaf, M. E., Carducci, M. A., Rodríguez, R., Hammers, H.-J., et al. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822895e5 · Cited by 79
“However, several studies have supported the high throughput value of TMA usage and the adequate representation of overall expression levels using multiple TMA spots.5 In summary, we found evidence of activation of both the mTOR and hypoxia-induced pathways in primary and metastatic ccRCC. PTEN loss seems to be an earl…”
BackgroundInfluentialKoslowski, M., Luxemburger, U., Türeci, Ö., & Şahin, U. (2010) · Oncogene · doi:10.1038/onc.2010.481 · Cited by 90
Elser, M., Borsig, L., Hassa, P. O., Erener, S., Messner, S., Valovka, T., Keller, S., Gassmann, M., & Hottiger, M. O. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0377 · Cited by 84
“to be supportive, if not causative, in cancer (6-8).”
BackgroundThe VHL protein recruits a novel KRAB‐A domain protein to repress HIF‐1α transcriptional activity
Li, Z., Wang, D., Na, X., Schoen, S. R., Messing, E. M., & Wu, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg173 · Cited by 89
Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression
Yang, G., Shi, R., & Zhang, Q. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218162 · Cited by 80
Jia, P., Chen, H., Kang, H., Qi, J., Zhao, P., Jiang, M., Guo, L., Zhou, Q., Qian, N. D., Zhou, H., et al. (2016) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.35793 · Cited by 83
Corn, P. G., McDonald, E. R., Herman, J. G., & El‐Deiry, W. S. (2003) · Nature Genetics · doi:10.1038/ng1254 · Cited by 84
MCPIP1 contributes to clear cell renal cell carcinomas development
Ligęza, J., Marona, P., Gach, N., Lipert, B. A., Miękus, K., Wilk, W., Jaszczyński, J., Stelmach, A., Łoboda, A., Dulak, J., et al. (2017) · Angiogenesis · doi:10.1007/s10456-017-9540-2 · Cited by 81
“This protein is responsible for assigning other proteins for proteasomal degradation and has a well-documented role in ccRCC development [32, 33].”
Shin, D. H., Dier, U., Melendez, J. A., & Hempel, N. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.09.001 · Cited by 79
Hypoxia-inducible factor in cancer angiogenesis: Structure, regulation and clinical perspectives
Otrock, Z. K., Hatoum, H. A., Awada, A. H., Ishak, R. S., & Shamseddine, A. I. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2009.01.001 · Cited by 87
“[53] Ohh M, Park CW, Ivan M, et al.”
BackgroundCellular reaction to hypoxia: sensing and responding to an adverse environment
Papandreou, I., Powell, A. A., Lim, A. L., & Denko, N. C. (2004) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.06.054 · Cited by 90
Copper Is Required for Cobalt-Induced Transcriptional Activity of Hypoxia-Inducible Factor-1
Qiu, L., Ding, X., Zhang, Z., & Kang, Y. J. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194662 · Cited by 83
Hahn, O. M., & Stadler, W. M. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000245316.82391.52 · Cited by 77
An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor
Shirai, Y., Chow, C. C. T., Kambe, G., Suwa, T., Kobayashi, M., Takahashi, I., Harada, H., & Nam, J. (2021) · Cancers · doi:10.3390/cancers13112813 · Cited by 79
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.